WASHINGTON, Oct. 16 (Xinhua) -- The U.S. National Institutes of Health (NIH) has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19, said a statement of the agency on Friday.
Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays.